Sarcoma,Soft Tissue Clinical Trial
Official title:
Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction: A Randomized Controlled Trial
This study intends to determine if any correlation exists between administration of TXA or not to musculoskeletal oncology patients undergoing endoprosthetic reconstruction and blood loss and blood transfusion rates.
Resection of bony and soft tissue tumors with endoprosthetic reconstruction often presents a significant risk of perioperative blood loss requiring transfusion. Tranexamic acid (TXA) is an antifibrinolytic that is commonly used to reduce blood loss in orthopedic procedures, most often arthroplasty. The aim of this study is to determine in a randomized controlled fashion if there is any difference in perioperative blood loss and blood transfusion rates when TXA is used compared to when it is not used in patients undergoing radical resection of bone and soft tissue sarcomas with endoprosthetic reconstruction. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04577014 -
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT06114004 -
Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc)
|
Phase 2 | |
Completed |
NCT01949506 -
(SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas
|
N/A | |
Recruiting |
NCT04595994 -
Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma
|
Phase 1 | |
Recruiting |
NCT05235100 -
Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma
|
Phase 2 | |
Completed |
NCT04991883 -
Analysis of the Molecular Profile of the Mixofibrosarcoma of the Extremities
|
||
Recruiting |
NCT04122872 -
GISAR German Interdisciplinary Sarcoma Registry
|
||
Recruiting |
NCT04910126 -
Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma
|
Phase 2 | |
Recruiting |
NCT04219202 -
Neoadjuvant Irradiation of Retroperitoneal Soft Tissue Sarcoma With Ions Retro-Ion
|
N/A | |
Recruiting |
NCT04028479 -
The Registry of Oncology Outcomes Associated With Testing and Treatment
|
||
Recruiting |
NCT05886634 -
A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
|
Phase 2 | |
Recruiting |
NCT05167994 -
Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma
|
Phase 2 | |
Recruiting |
NCT04673942 -
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05813327 -
Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT04172805 -
Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma
|
Phase 2 | |
Active, not recruiting |
NCT04887298 -
Study of Liposomal Annamycin for the Treatment of Subjects With Soft-Tissue Sarcomas (STS) With Pulmonary Metastases
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03600649 -
Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
|
Phase 1 | |
Recruiting |
NCT05894018 -
Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarcoma
|
Phase 2 | |
Recruiting |
NCT06263231 -
A Study to Investigate Efficacy & Safety of INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
|
Phase 3 | |
Completed |
NCT01985295 -
Combined Modality Treatment of Sarcomas of the Extremities
|
Phase 1 |